CD226 and neoplasm: The DNAM-1 chimeric receptor could confer a dual advantage to NK cells: (i) specific recognition of ligands such as PVR and Nectin-2, which are highly expressed in tumor cells, but importantly absent or poorly expressed in normal cells, and (ii) its overexpression, which should result in a favorable molecular imbalance with respect to the normal expression of competing receptors (TIGIT, TACTILE, PVRIG), leading to its increased binding to PVR and Nectin-2.